On this page
Azelastine Hydrochloride
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Azelastine Hydrochloride | .5 mg/mL | 860805 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Histamine H1 Receptor Antagonists [MoA] | MoA | All 136 members |
| Histamine-1 Receptor Antagonist [EPC] | EPC | All 134 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 210092-001 | AZELASTINE HYDROCHLORIDE | SOLUTION/DROPS | AZELASTINE HYDROCHLORIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | February 25, 2020 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260908). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE: Azelastine hydrochloride ophthalmic solution, 0.05% is indicated for the treatment of itching of the eye associated with allergic conjunctivitis.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION: The recommended dose is one drop instilled into each affected eye twice a day.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS: Azelastine hydrochloride ophthalmic solution, 0.05% is contraindicated in persons with known or suspected hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS Azelastine hydrochloride ophthalmic solution, 0.05% is for topical ophthalmic use only and not for injection or oral use.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In controlled multiple-dose studies where patients were treated for up to 56 days, the most frequently reported adverse reactions were transient eye burning/stinging (approximately 30%), headaches (approximately 15%) and bitter taste (approximately 10%). The occurrence of these events was generally mild. The following events were reported in 1% to 10% of patients: asthma, conjunctivitis, dyspnea, eye pain, fatigue, influenza-like symptoms, pharyngitis, pruritus, rhinitis and temporary blurring. Some of these events were similar to the underlying disease being studied. To report SUSPECTED ADVERSE REACTIONS, contact Fosun Pharma USA Inc. at 1-866-611-3762 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Azelastine hydrochloride ophthalmic solution, 0.05% is a sterile ophthalmic solution containing azelastine hydrochloride, a relatively selective H 1 -receptor antagonist for topical administration to the eyes. Azelastine hydrochloride is a white crystalline powder with a molecular weight of 418.37. Azelastine hydrochloride is sparingly soluble in water, methanol and propylene glycol, and slightly soluble in ethanol, octanol and glycerine. Azelastine hydrochloride is a racemic mixture with a melting point of 225°C. The chemical name for azelastine hydrochloride is (±)-1-(2H)-phthalazinone,4-[(4-chlorophenyl) methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride and is represented by the following chemical structure: Empirical chemical structure: C 22 H 24 CIN 3 O•HCl Each mL of azelastine hydrochloride ophthalmic solution, 0.05% contains: Active: 0.5 mg azelastine hydrochloride, equivalent to 0.457 mg of azelastine base; Preservative: 0.25 mg benzalkonium chloride solution (50%) USP-NF; Inactives: disodium edetate dihydrate, hypromellose, sorbitol solution, sodium hydroxide and water for injection. It has a pH of approximately 5 to 6.5 and an osmolality of approximately 271 to 312 mOsmol/L. chemical structure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Azelastine Hydrochloride Ophthalmic Solution USP, 0.05% is supplied as follows: 6 mL (NDC# 60505-0578-4) solution in a translucent 11 mL HDPE container with a LDPE dropper tip, and a white HDPE screw cap. Storage Store UPRIGHT at 20oC to 25oC (68oF to 77oF) [See USP Controlled Room Temperature]. Azelastine Hydrochloride Ophthalmic Solution, USP 0.05% Manufactured by: Manufactured for: Apotex Inc. Apotex Corp. Toronto, Ontario Weston, FL Canada M9L 1T9 33326 September 2025
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: AZELASTINE HYDROCHLORIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class II | July 2, 2025 | Apotex Corp. | Lack of Assurance of Sterility | Ongoing |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 46708-506-06 | 46708-506 | Alembic Pharmaceuticals Limited | 1 BOTTLE in 1 CARTON (46708-506-06) / 6 mL in 1 BOTTLE | March 20, 2019 |
| 60505-0578-4 | 60505-0578 | Apotex Corp. | 1 BOTTLE, PLASTIC in 1 CARTON (60505-0578-4) / 6 mL in 1 BOTTLE, PLASTIC | December 1, 2009 |
| 72266-141-01 | 72266-141 | Fosun Pharma USA Inc | 1 BOTTLE, PLASTIC in 1 CARTON (72266-141-01) / 6 mL in 1 BOTTLE, PLASTIC | September 8, 2020 |
| 68083-287-01 | 68083-287 | Gland Pharma Limited | 1 BOTTLE, PLASTIC in 1 BOX (68083-287-01) / 6 mL in 1 BOTTLE, PLASTIC | February 25, 2020 |
| 61314-308-02 | 61314-308 | Sandoz Inc | 1 BOTTLE, PLASTIC in 1 CARTON (61314-308-02) / 6 mL in 1 BOTTLE, PLASTIC | March 21, 2013 |
| 70069-091-01 | 70069-091 | Somerset Therapeutics, LLC | 1 BOTTLE in 1 CARTON (70069-091-01) / 6 mL in 1 BOTTLE | April 8, 2019 |
| 47335-938-90 | 47335-938 | Sun Pharmaceutical Industries, Inc. | 1 BOTTLE, PLASTIC in 1 BOX (47335-938-90) / 6 mL in 1 BOTTLE, PLASTIC | May 31, 2010 |
| 46708-506 | 46708-506 | Alembic Pharmaceuticals Limited | — | March 20, 2019 |
| 60505-0578 | 60505-0578 | Apotex Corp. | — | December 1, 2009 |
| 72266-141 | 72266-141 | Fosun Pharma USA Inc | — | September 8, 2020 |
| 68083-287 | 68083-287 | Gland Pharma Limited | — | February 25, 2020 |
| 61314-308 | 61314-308 | Sandoz Inc | — | March 21, 2013 |
| 70069-091 | 70069-091 | Somerset Therapeutics, LLC | — | April 8, 2019 |
| 47335-938 | 47335-938 | Sun Pharmaceutical Industries, Inc. | — | May 31, 2010 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.